重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗难治性慢性痛风性关节炎的临床分析

doi:10.20223/j.cnki.1000-8535.2025.09.015

广州医药 ›› 2025, Vol. 56 ›› Issue (9): 1264-1267.DOI: 10.20223/j.cnki.1000-8535.2025.09.015

重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗难治性慢性痛风性关节炎的临床分析

蔡晓燕¹, 汪媚娟¹, 范志勇¹, 黄荣姬²

1 广州市受助人员安置中心内科（广东广州 510430）;
2 广州中医药大学顺德医院风湿科（广东佛山 528333）

收稿日期:2024-12-11 出版日期:2025-09-20 发布日期:2025-10-31
基金资助:
佛山市科技局医学类科技攻关项目（2220001004444）

Clinical analysis of recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein in refractory chronic gouty arthritis

CAI Xiaoyan¹, WANG Meijuan¹, FAN Zhiyong¹, HUANG Rongji²

1 Department of Medical, Guangzhou Recipinet Placement Center, Guangzhou 510430, China;
2 Department of Rheumatology, Shunde Hospital Guangzhou University of Chinese Medicine, Foshan 528333, China

Received:2024-12-11 Online:2025-09-20 Published:2025-10-31

摘要/Abstract

摘要： 目的评估重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白（rhTNRF：Fc）治疗难治性慢性痛风性关节炎的临床疗效及安全性。方法选取2022年1月一2023年12月广州中医药大学顺德医院风湿科门诊收治的46例难治性痛风性关节炎患者,分为观察组和对照组两组,对照组规范使用降尿酸药物治疗,观察组在对照组治疗的基础上联合使用rhTNRF：Fc至少12周,在0、12、24、48周观察两组的血尿酸（sUA）、肿瘤坏死因子-α（TNF-α）、关节肌肉骨骼超声变化、痛风发作例数、肝肾功能等指标。结果观察组与对照组sUA无明显差别（P>0.05）,TNF-α水平明显下降（P<0.05）,滑膜炎、关节积液影像表现减少（P<0.05）,痛风发作例数明显减少（P<0.05）,观察期间肝肾功能正常,无患者因不良反应退出研究。结论 rhTNRF：Fc对难治性慢性痛风性关节炎安全有效。

关键词: 重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白;, 难治性慢性痛风性关节炎, 肿瘤坏死因子-α

Abstract: Objective To explore the efficacy and safety of recombinant human type II tumor necrosis factor receptor-antibody fusion protein（rhTNRF：Fc）in refractory chronic gouty arthritis. Methods From January 2022 to December 2023,46 cases of refractory chronic gouty arthritis in the Rheumatology Outpatient Department,Shunde Hospital Guangzhou University of Chinese Medicine were selected and divided into an observation group and a control group. The control group received routine treatment,while the observation group received rhTNRF：Fc treatment additionally for at least 12 weeks,two groups of indicators such as serum urine acid（sUA）,TNF-α,changes in musculoskeletal ultrasound,number of gout attacks,hepatic and renal function at 0,12,24,and 48 weeks were observed. Results There was no significant difference in sUA between the observation group and the control group（P>0. 05）,TNF-α significantly decreased（P<0. 05）,synovitis and joint effusion imaging manifestations reduced（P<0. 05）,number of gout attacks decreased（P<0. 05）. During the observation period,liver and kidney function were normal,and no patients withdrew from the study due to adverse reactions. Conclusions Using rhTNRF：Fc is safe and effective in treating refractory chronic gouty arthritis.

Key words: recombinant human type II tumor necrosis factor receptor-antibody fusion protein, refractory chronic gouty arthritis, tumor necrosis factor-α

蔡晓燕, 汪媚娟, 范志勇, 黄荣姬. 重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗难治性慢性痛风性关节炎的临床分析[J]. 广州医药, 2025, 56(9): 1264-1267.

CAI Xiaoyan, WANG Meijuan, FAN Zhiyong, HUANG Rongji. Clinical analysis of recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein in refractory chronic gouty arthritis[J]. Guangzhou Medical Journal, 2025, 56(9): 1264-1267.

参考文献

[1] 刘湘源,郑晓娟.尿酸持续达标是难治性痛风治疗的关键[J].北京大学学报(医学版),2012,44(2):168-170.
[2] 杨雪,刘磊,朱小霞,等.2015年美国风湿病学会/欧洲抗风湿病联盟痛风分类标准评述[J].中华风湿病学杂志,2016,20(2):141-143.
[3] 赵东宝,万伟,徐霞.痛风诊断标准的演变及其影像学检查在临床中的应用[J].诊断学理论与实践,2014,13(3):229-231.
[4] MAEKAWA M,TOMIDA H,AOKI T,et al.Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure[J].Intern Med,2014,53(6):609-612.
[5] 张雄峰,李正胜,刘正奇.难治性痛风性关节炎的临床分析[J].中国骨与关节杂志,2017,6(8):611-614.
[6] 朱克强,王晨,惠晓艳,等.肿瘤坏死因子α在痛风性关节炎发病机制中的作用研究进展[J].浙江医学,2020,42(6):638-641.
[7] HAO G,DUAN W,SUN J,et al.Effects of febuxostat on serum cytokines IL-1,IL-4,IL-6,IL-8,TNF-α and COX-2[J].Exp Ther Med,2019,17(1):812-816.
[8] MEHTA A K,GRACIAS D T,CROFT M.TNF activity and T cells[J].Cytokine,2018(101):14-18.
[9] 章晓云,曾浩,李华南,等.痛风性关节炎的发病机制及中医药治疗研究进展[J].中国实验方剂学杂志,2022,28(11):256-267.
[10] CALVO-ARANDA E,SANCHEZ-ARAMDA F M.Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra[J].Rheumatology(Oxford),2021,60(11):e375-e377.
[11] LATOURTE A,EA H K,FRAZIER A,et al.Tocilizumab in symptomatic calcium pyrophosphate deposition disease:A pilot study[J].Ann Rheum Dis,2020,79(8):1126-1128.
[12] BECKER M A,SCHUMACHER H R JR,WORTMANN R L,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout[J].N Engl J Med,2005,353(23):2450-2461.
[13] 周雨亭,李江涛.抗肿瘤坏死因子α及白细胞介素6类生物制剂治疗痛风的研究进展[J].中华风湿病学杂志,2023,27(2):134-138.

重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗难治性慢性痛风性关节炎的临床分析

Clinical analysis of recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein in refractory chronic gouty arthritis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价